Vinge has advised BICO Group AB on the deal, while Baker McKenzie advised the Joint Global Coordinators.
The Board of Directors of BICO Group AB has resolved on a directed issue of 4,250,000 series B shares at a subscription price of SEK 480 per share (the “Share Issue”), which means that the Company raises SEK 2,040,000,000 million before transaction costs.
The subscription price in the Share Issue has been determined through an accelerated bookbuilding procedure, performed by Carnegie Investment Bank AB (publ), J.P. Morgan AG, ABG Sundal Collier AB and Bryan, Garnier & Co, and corresponds to a discount of approximately 5.6 percent compared to the closing price as of October 7, 2021 of the BICO share of series B on Nasdaq Stockholm. In addition to a strong support from existing shareholders, several new institutional investors participated in the Share Issue.
BICO intends to use the issue proceeds to finance the acquisition of QInstruments as well as to further promote the Company’s acquisition agenda and create financial preparedness regarding new possibilities.
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.
Vinge’s team consisted of Anders Strid (Picture), Edin Agic and Adrian Filipovic.
The Baker McKenzie team consisted of Henric Roth, Joakim Falkner and Per Blom in Stockholm as well as Megan Schellinger in London.
Involved fees earner: Per Blom – Baker McKenzie; Joakim Falkner – Baker McKenzie; Henric Roth – Baker McKenzie; Megan Schellinger – Baker McKenzie; Edin Agic – Vinge; Adrian Filipovic – Vinge; Anders Strid – Vinge;